Big Pharma likely to endure Trump's tariff, pricing pressures, but threats to generics persist: S&P
While the Trump administration’s threat of pharmaceutical import tariffs and most favored nation drug pricing has weighed heavily on the pharmaceutical industry in recent months, many branded drugmakers are well-positioned to handle the pressures, S&P Global said in a new report.
While the Trump administration’s threat of pharmaceutical import tariffs and most favored nation drug pricing has weighed heavily on the pharmaceutical industry in recent months, many branded drugmakers are well-positioned to handle the pressures, S&P Global said in a new report.
